More drugs to get QR codes amid fight against fake products

1. At a Glance

• The Union Health Ministry has amended the Drugs Rules, 1945 to expand Schedule H2, mandating QR/barcode-based track-and-trace on critical drug categories. [1]
• New categories brought in: all vaccines, antimicrobials, narcotic & psychotropic drugs (covered under NDPS Act, 1985), and all anti-cancer drugs. [1][2]
• The measure is India's primary legislative instrument to curb spurious (counterfeit/substandard) medicines entering the supply chain. [3]
• UPSC relevance: intersects GS-II (health policy, regulatory bodies), GS-III (pharma sector, IPR, AMR), and governance/ethics dimensions.

2. Why in the News

• June 2026: Union Health Ministry notified the amendment to Drugs Rules, 1945 expanding Schedule H2 scope; notification dated around 25 June 2026. [1][2]
• Implementation dates announced: 1 July 2026 for vaccines, anti-cancer, and narcotic/psychotropic drugs; 1 July 2028 for antimicrobials (longer runway given supply-chain complexity). [1]
• Backdrop: CDSCO flagged 4 spurious drugs and 194 quality-test failures in February 2026 alone, underscoring persistent counterfeiting problem. [4]

3. Background & Evolution

• Drugs Rules, 1945 — the principal subordinate legislation under the Drugs and Cosmetics Act, 1940; periodically amended to tighten pharma regulation.
• Schedule H (pre-existing): restricts sale of specified drugs to prescription only; does not mandate traceability technology.
• Schedule H1 (introduced 2013): stricter prescription controls for habit-forming, third-line antibiotic, and narcotic drugs; required pharmacist record-keeping. [5]
• Schedule H2: created to layer a digital track-and-trace dimension on top of Schedule H controls — manufacturers must embed machine-readable product identity on packaging.
• 2023: Centre introduced initial traceability rules for pharma exports; deadline was later extended. [6]
• 2024 (August): DCGI introduced new traceability rules; pharma companies were put on notice to implement QR codes to combat counterfeits. [7][8]
• 2026: Current amendment widens the net to high-risk drug categories (vaccines, antimicrobials, NDPS drugs, anti-cancer). [1]

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• India is the world's largest generic drug exporter by volume; counterfeit infiltration risks export market access and brand credibility in regulated markets (US FDA, EMA). [8]
• QR code compliance imposes upfront capex on small/medium pharma manufacturers; larger players already invested post-2024 DCGI directives. [7]
• Spurious drugs cause economic losses to legitimate producers and erode patient trust, reducing demand for formal-sector medicines.

Social / Public Health

• WHO estimates ~10% of medical products in low/middle-income countries are substandard or falsified; India, as a major producer, must ensure supply-chain integrity both domestically and for exports. [3]
• Anti-cancer and vaccine counterfeiting carries direct mortality risk; QR traceability allows patients and providers to verify authenticity at point of dispensation.
• Antimicrobial resistance (AMR): counterfeit or substandard antimicrobials with incorrect dosing accelerate AMR — a stated secondary benefit of the track-and-trace framework.

Legal / Constitutional

• Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945 are Union List subjects (Entry 19, List I — "standards of quality for goods").
• NDPS Act, 1985: concurrent law with strict penal provisions; extending QR coding to NDPS-covered substances strengthens existing chain-of-custody controls.
• Non-compliance with Schedule H2 packaging rules = misbranded/adulterated drug offence under the Drugs and Cosmetics Act.

Scientific / Technological

• QR (Quick Response) codes encode 2D data; when linked to a centralised database, enable real-time supply-chain verification from manufacturer → distributor → retailer → patient.
• Framework enables serialisation (unique item-level identity) — aligned with WHO guidance on medicine track-and-trace and similar to EU Falsified Medicines Directive (FMD) model.
• Future integration with Ayushman Bharat Digital Mission (ABDM) health ID ecosystem could enable patient-level medicine verification.

Administrative / Governance

• Staggered implementation (2026 for high-risk drugs; 2028 for antimicrobials) reflects recognition of SME capacity constraints in pharma manufacturing.
• CDSCO is the nodal enforcer; state drug controllers handle ground-level inspections — federal co-ordination is a structural challenge.
• Drug Alert Portal and CDSCO's monthly quality-failure notifications (e.g., 194 failures in Feb 2026) form the surveillance backbone alongside track-and-trace. [4]

Ethical / Governance

• Transparency dimension: QR codes make the supply chain legible to end-consumers, empowering patients to self-verify — a shift from opaque B2B-only compliance.
• Accountability gap: without a centralised, publicly accessible database linked to QR codes, the mandate is only as strong as back-end infrastructure.

6. Recent Developments (last 12–18 months)

• Feb 2026: CDSCO flagged 4 spurious drugs; 194 drug batches failed quality tests in a single month. [4]
• Nov 2024: CDSCO flagged 2 spurious drugs; 111 failed quality tests. [9]
• Aug 2024: DCGI issued new traceability rules placing pharma companies on notice to implement QR codes for anti-counterfeit purposes. [7]
• Jul 2024: Industry reports noted pharma companies were already on track to comply with QR code mandates ahead of formal regulatory action. [8]
• June 25–26, 2026: MoHFW notified the formal amendment to Drugs Rules, 1945 expanding Schedule H2 to cover vaccines, antimicrobials, NDPS and anti-cancer drugs. [1][2]

7. Prelims Hooks

1. Schedule H2 is a schedule under the Drugs Rules, 1945, not a standalone Act.
2. The parent Act is the Drugs and Cosmetics Act, 1940; Drugs Rules, 1945 are its subordinate legislation.
3. QR code mandate covers drugs under the NDPS Act, 1985 — narcotic and psychotropic substances.
4. Four new categories brought under Schedule H2 QR mandate: vaccines; antimicrobials; narcotic & psychotropic drugs; anti-cancer drugs.
5. Effective date for antimicrobials under the QR mandate: 1 July 2028 (not 2026).
6. Effective date for vaccines, anti-cancer, NDPS drugs: 1 July 2026.
7. The QR code must be on the primary packaging label; if space is insufficient, on the secondary packaging label.
8. QR code must include the manufacturing licence number — a compliance and traceability requirement.
9. Implementing ministry: Ministry of Health & Family Welfare (MoHFW); regulatory enforcement: CDSCO under DCGI.
10. WHO classifies fake/substandard drugs as "substandard and falsified medical products" — distinct from "counterfeit" (a term with IP-law implications). [3]
11. Schedule H1 (2013) was the predecessor prescription-control schedule for habit-forming/narcotic drugs; Schedule H2 adds digital traceability.
12. The earlier (2023) QR-code track-and-trace rules applied specifically to pharma exports; the 2026 amendment applies to domestic market categories. [6]
13. CDSCO publishes monthly drug quality alerts; flagging is distinct from the new QR code prevention mechanism.

8. Mains Relevance

GS Paper mapping:

• GS-II: Government policies and interventions for health; regulatory bodies (CDSCO/DCGI); issues relating to development and management of social sectors.
• GS-III: Indian economy — pharma sector; science and technology — QR/digital traceability; issues relating to intellectual property rights and counterfeiting.

Syllabus headings:

• GS-II: Issues relating to health, education, human resources.
• GS-III: Awareness in the fields of IT, Space, Computers, Robotics, Nano-technology, Bio-technology; indigenisation of technology and developing new technology.

Plausible Mains question stems:

1. "The expansion of Schedule H2 under the Drugs Rules, 1945 is a significant step in India's fight against spurious medicines. Critically examine its scope, implementation challenges, and potential impact on public health." (GS-II/III, 15 marks)
2. "Antimicrobial resistance (AMR) and counterfeit medicines are interlinked public health crises. How does the QR code-based track-and-trace system proposed in India address both challenges? What are its limitations?" (GS-II, 10 marks)
3. "Discuss the role of digital technologies in strengthening pharmaceutical supply-chain regulation in India, with reference to recent policy initiatives." (GS-III, 15 marks)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Schedule H vs H1 vs H2 confusion: Schedule H = prescription-only list; H1 (2013) = stricter prescription + pharmacist records for specific drugs; H2 = QR/barcode track-and-trace. These are distinct layers, not substitutes.
2. Wrong parent Act: Schedules H, H1, H2 are under Drugs Rules, 1945 (subordinate legislation), not directly under the Drugs and Cosmetics Act, 1940 — though the Act is the enabling statute.
3. Conflating CDSCO with FSSAI: CDSCO (under MoHFW) regulates drugs/cosmetics; FSSAI (also MoHFW) regulates food. Drug quality failures and QR mandates fall under CDSCO/DCGI.
4. Antimicrobial effective date: Antimicrobials get a later deadline (2028), not 2026. Assuming all categories take effect simultaneously is a common trap.
5. "Counterfeit" vs "spurious/falsified": In Indian law and WHO terminology, the preferred terms are spurious (Drugs and Cosmetics Act) or substandard and falsified (WHO); "counterfeit" carries IP-law connotations and is not the primary legal category used in Indian drug regulation.